Molecular basis of physiological heart growth: Fundamental concepts and new players

Nature Reviews Molecular Cell Biology

Volumn 14, Issue 1, 2013, Pages 38-48

  Maillet, Marjorie ^a   Van Berlo, Jop H ^a   Molkentin, Jeffery D ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; THYROID HORMONE; VASCULOTROPIN;

CLINICAL FEATURE; ENDOCRINE FUNCTION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART DEVELOPMENT; HEART VENTRICLE HYPERTROPHY; HUMAN; MEDICAL LITERATURE; MOLECULAR BIOLOGY; NONHUMAN; PHYSIOLOGY; POSTNATAL GROWTH; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; ENERGY METABOLISM; HEART; HEART FAILURE; HUMANS; MICE; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; THYROID HORMONES; TRANSCRIPTION, GENETIC;

EID: 84871518109     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm3495     Document Type: Review

References (121)

1. Bernardo, B. C., Weeks, K. L., Pretorius, L. & McMullen, J. R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Ther. 128, 191-227 (2010).
2. Heineke, J. & Molkentin, J. D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature Rev. Mol. Cell Biol. 7, 589-600 (2006).
3. Van Berlo, J. H., Maillet, M. & Molkentin, J. D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. (in the press).
4. Bergmann, O. et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98-102 (2009).
5. Kajstura, J. et al. Cardiomyogenesis in the aging and failing human heart. Circulation 126, 1869-1881 (2012).
6. Dorn, G. W. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49, 962-970 (2007).
7. Porrello, E. R., Widdop, R. E. & Delbridge, L. M. Early origins of cardiac hypertrophy: does cardiomyocyte attrition programme for pathological 'catch-up' growth of the heart? Clin. Exp. Pharmacol. Physiol. 35, 1358-1364 (2008).
8. Hopkins, S. F. Jr, McCutcheon, E. P. & Wekstein, D. R. Postnatal changes in rat ventricular function. Circ. Res. 32, 685-691 (1973).
9. Clubb, F. J. Jr & Bishop, S. P. Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy. Lab. Invest. 50, 571-577 (1984).
10. Eghbali, M., Wang, Y., Toro, L. & Stefani, E. Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc. Med. 16, 285-291 (2006).
11. Winsor, T. & Beckner, G. Hypertrophy of the heart; electrocardiographic distinction between physiologic and pathologic enlargement. Calif. Med. 82, 151-158 (1955).
12. Henschen, S. Skilanglauf and skiwettlauf: ein medizinische sportstudie. Mitt. Med. Klin. Uppsala 2, 15-18 (1899).
13. Nishimura, T., Yamada, Y. & Kawai, C. Echocardiographic evaluation of long-term effects of exercise on left ventricular hypertrophy and function in professional bicyclists. Circulation 61, 832-840 (1980).
14. Sugishita, Y., Koseki, S., Matsuda, M., Yamaguchi, T. & Ito, I. Myocardial mechanics of athletic hearts in comparison with diseased hearts. Am. Heart J. 105, 273-280 (1983).
15. Dickhuth, H. H., Reindell, H., Lehmann, M. & Keul, J. [Capacity for regression of the athletic heart]. Z. Kardiol. 74 (Suppl. 7), 135-143 (1985).
16. Schannwell, C. M. et al. Left ventricular hypertrophy and diastolic dysfunction in healthy pregnant women. Cardiology 97, 73-78 (2002).
17. Janz, K. F., Dawson, J. D. & Mahoney, L. T. Predicting heart growth during puberty: The Muscatine Study. Pediatrics 105, e63 (2000).
18. Hew, K. W. & Keller, K. A. Postnatal anatomical and functional development of the heart: a species comparison. Birth Defects Res. B. Dev. Reprod. Toxicol. 68, 309-320 (2003).
19. Pluim, B. M., Zwinderman, A. H., van der Laarse, A. & van der Wall, E. E. The athlete's heart. A meta-analysis of cardiac structure and function. Circulation 101, 336-344 (2000).
20. Ehsani, A. A., Hagberg, J. M. & Hickson, R. C. Rapid changes in left ventricular dimensions and mass in response to physical conditioning and deconditioning. Am. J. Cardiol. 42, 52-56 (1978).
21. Maron, B. J., Pelliccia, A., Spataro, A. & Granata, M. Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. Br. Heart J. 69, 125-128 (1993).
22. Sarquella-Brugada, G. et al. Genetics of sudden cardiac death in children and young athletes. Cardiol. Young 24, 1-15 (2012).
23. Patten, I. S. et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485, 333-338 (2012).
24. Heiss, H. W. et al. Studies on the regulation of myocardial blood flow in man. I. : Training effects on blood flow and metabolism of the healthy heart at rest and during standardized heavy exercise. Bas. Res. Cardiol. 71, 658-675 (1976).
25. Pelliccia, A. et al. Coronary arteries in physiological hypertrophy: echocardiographic evidence of increased proximal size in elite athletes. Int. J. Sports Med. 11, 120-126 (1990).
26. Laughlin, M. H., Bowles, D. K. & Duncker, D. J. The coronary circulation in exercise training. Am. J. Physiol. Heart Circ. Physiol. 302, H10-H23 (2012).
27. Lopaschuk, G. D. & Jaswal, J. S. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J. Cardiovasc. Pharmacol. 56, 130-140 (2010).
28. Gertz, E. W., Wisneski, J. A., Stanley, W. C. & Neese, R. A. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J. Clin. Invest. 82, 2017-2025 (1988).
29. Abel, E. D. & Doenst, T. Mitochondrial adaptations to physiological versus pathological cardiac hypertrophy. Cardiovasc. Res. 90, 234-242 (2011).
30. Wilkins, B. J. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94, 110-118 (2004).
31. Burgess, M. L. et al. Exercise-and hypertension-induced collagen changes are related to left ventricular function in rat hearts. Am. J. Physiol. 270, H151-H159 (1996).
32. Jin, H. et al. Effects of exercise training on cardiac function, gene expression, and apoptosis in rats. Am. J. Physiol. Heart Circ. Physiol. 279, H2994-H3002 (2000).
33. Neri Serneri, G. G. et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 89, 977-982 (2001).
34. Bellomo, D. et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86, e29-e35 (2000).
35. Karpanen, T. et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ. Res. 103, 1018-1026 (2008).
36. Bry, M. et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 122, 1725-1733 (2010).
37. Stubbe, P., Gatz, J., Heidemann, P., Muhlen, A. & Hesch, R. Thyroxine-binding globulin, triiodothyronine, thyroxine and thyrotropin in newborn infants and children. Horm. Metab. Res. 10, 58-61 (1978).
38. Hadj-Sahraoui, N., Seugnet, I., Ghorbel, M. T. & Demeneix, B. Hypothyroidism prolongs mitotic activity in the post-natal mouse brain. Neurosci. Lett. 280, 79-82 (2000).
39. Morkin, E. Regulation of myosin heavy chain genes in the heart. Circulation 87, 1451-1460 (1993).
40. Arsanjani, R., McCarren, M., Bahl, J. J. & Goldman, S. Translational potential of thyroid hormone and its analogs. J. Mol. Cell. Cardiol. 51, 506-511 (2011).
41. Kenessey, A. & Ojamaa, K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J. Biol. Chem. 281, 20666-20672 (2006).
42. Kenessey, A., Sullivan, E. A. & Ojamaa, K. Nuclear localization of protein kinase C-α induces thyroid hormone receptor-α1 expression in the cardiomyocyte. Am. J. Physiol. Heart Circ. Physiol. 290, H381-H389 (2006).
43. Belakavadi, M., Saunders, J., Weisleder, N., Raghava, P. S. & Fondell, J. D. Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-α1 and involves targeted covalent histone modifications. Endocrinology 151, 2946-2956 (2010).
44. Brownsey, R. W., Boone, A. N. & Allard, M. F. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc. Res. 34, 3-24 (1997).
45. Shiojima, I. & Walsh, K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 20, 3347-3365 (2006).
46. Araki, E. et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372, 186-190 (1994).
47. Burks, D. J. et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 407, 377-382 (2000).
48. Belke, D. D. et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109, 629-639 (2002).
49. Hu, P. et al. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am. J. Physiol. Heart Circ. Physiol. 285, H1261-H1269 (2003).
50. Sena, S. et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J. Mol. Cell. Cardiol. 46, 910-918 (2009).
51. Boudina, S. et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119, 1272-1283 (2009).
52. Efstratiadis, A. Genetics of mouse growth. Int. J. Dev. Biol. 42, 955-976 (1998).
53. Sutton, J. & Lazarus, L. A. Growth hormone in exercise: comparison of physiological and pharmacological stimuli. J. Appl. Physiol. 41, 523-527 (1976).
54. Baker, J., Liu, J. P., Robertson, E. J. & Efstratiadis, A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75, 73-82 (1993).
55. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J. & Efstratiadis, A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75, 59-72 (1993).
56. Reiss, K. et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl Acad. Sci. USA 93, 8630-8635 (1996).
57. Delaughter, M. C., Taffet, G. E., Fiorotto, M. L., Entman, M. L. & Schwartz, R. J. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 13, 1923-1929 (1999).
58. McMullen, J. R. et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110α) pathway. J. Biol. Chem. 279, 4782-4793 (2004).
59. Kim, J. et al. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol. Endocrinol. 22, 2531-2543 (2008).
60. Moellendorf, S. et al. IGF-IR signaling attenuates the age-related decline of diastolic cardiac function. Am. J. Physiol. Endocrinol. Metab. 303, e213-e222 (2012).
61. Patel, A. et al. Canonical TRP channels and mechanotransduction: from physiology to disease states. Pflugers Arch. 460, 571-581 (2010).
62. Musarς, A., McCullagh, K. J., Naya, F. J., Olson, E. N. & Rosenthal, N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400, 581-585 (1999).
63. Maroto, R. et al. TRPC1 forms the stretch-activated cation channel in vertebrate cells. Nature Cell Biol. 7, 179-185 (2005).
64. Spassova, M. A., Hewavitharana, T., Xu, W., Soboloff, J. & Gill, D. L. A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc. Natl Acad. Sci. USA 103, 16586-16591 (2006).
65. Seth, M. et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 105, 1023-1030 (2009).
66. Wu, X., Eder, P., Chang, B. & Molkentin, J. D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc. Natl Acad. Sci. USA 107, 7000-7005 (2010).
67. Shai, S. Y. et al. Cardiac myocyte-specific excision of the β1 integrin gene results in myocardial fibrosis and cardiac failure. Circ. Res. 90, 458-464 (2002).
68. Johnston, R. K. et al. β3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J. 23, 2759-2771 (2009).
69. Cox, L., Umans, L., Cornelis, F., Huylebroeck, D. & Zwijsen, A. A broken heart: a stretch too far: an overview of mouse models with mutations in stretch-sensor components. Int. J. Cardiol. 131, 33-44 (2008).
70. Linke, W. A. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc. Res. 77, 637-648 (2008).
71. Herman, D. S. et al. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366, 619-628 (2012).
72. Shioi, T. et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537-2548 (2000).
73. McMullen, J. R. et al. Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100, 12355-12360 (2003).
74. Luo, J. et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 25, 9491-9502 (2005).
75. Lu, Z. et al. Loss of cardiac phosphoinositide 3-kinase p110α results in contractile dysfunction. Circulation 120, 318-325 (2009).
76. Crackower, M. A. et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110, 737-749 (2002).
77. McManus, E. J. et al. The in vivo role of PtdIns(3, 4, 5) P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J. 23, 2071-2082 (2004).
78. Mora, A. et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J. 22, 4666-4676 (2003).
79. Oudit, G. Y. et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 37, 449-471 (2004).
80. Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728-1731 (2001).
81. Chen, W. S. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203-2208 (2001).
82. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349-38352 (2001).
83. DeBosch, B. et al. Akt1 is required for physiological cardiac growth. Circulation 113, 2097-2104 (2006).
84. Shioi, T. et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22, 2799-2809 (2002).
85. Matsui, T. et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277, 22896-22901 (2002).
86. Condorelli, G. et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl Acad. Sci. USA 99, 12333-12338 (2002).
87. Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108-2118 (2005).
88. Shiraishi, I. et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 94, 884-891 (2004).
89. Rota, M. et al. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ. Res. 97, 1332-1341 (2005).
90. Haq, S. et al. Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. J. Cell. Biol. 151, 117-130 (2000).
91. Antos, C. L. et al. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 99, 907-912 (2002).
92. Michael, A. et al. Glycogen synthase kinase-3β regulates growth, calcium homeostasis, and diastolic function in the heart. J. Biol. Chem. 279, 21383-21393 (2004).
93. Skurk, C. et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 280, 20814-20823 (2005).
94. Malhowski, A. J. et al. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. Hum. Mol. Genet. 20, 1290-1305 (2011).
95. Wang, Y. et al. Rheb activates protein synthesis and growth in adult rat ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 45, 812-820 (2008).
96. Shen, W. H. et al. Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function. J. Biol. Chem. 283, 13842-13849 (2008).
97. Zhang, D. et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 120, 2805-2816 (2010).
98. Shende, P. et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 123, 1073-1082 (2011).
99. McMullen, J. R. et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol. 24, 6231-6240 (2004).
100. Tsukada, J., Yoshida, Y., Kominato, Y. & Auron, P. E. The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine 54, 6-19 (2011).
101. Bostrom, P. et al. C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143, 1072-1083 (2010).
102. Bueno, O. F. et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341-6350 (2000).
103. Lips, D. J. et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109, 1938-1941 (2004).
104. Purcell, N. H. et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc. Natl Acad. Sci. USA 104, 14074-14079 (2007).
105. Kehat, I. et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ. Res. 108, 176-183 (2011).
106. Kehat, I. & Molkentin, J. D. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann. NY Acad. Sci. 1188, 96-102 (2010).
107. Horman, S., Beauloye, C., Vanoverschelde, J. L. & Bertrand, L. AMP-activated protein kinase in the control of cardiac metabolism and remodeling. Curr. Heart Fail. Rep. 9, 164-173 (2012).
108. Shibata, R. et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nature Med. 10, 1384-1389 (2004).
109. Zarrinpashneh, E. et al. AMPKα2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem. Biophys. Res. Commun. 376, 677-681 (2008).
110. Zhang, P. et al. AMP activated protein kinase-α2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52, 918-924 (2008).
111. Sakamoto, K. et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKα2 but not AMPKα1. Am. J. Physiol. Endocrinol. Metab. 290, e780-e788 (2006).
112. Ikeda, Y. et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J. Biol. Chem. 284, 35839-35849 (2009).
113. Gundewar, S. et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 104, 403-411 (2009).
114. Maloyan, A. et al. Exercise reverses preamyloid oligomer and prolongs survival in αB-crystallin-based desmin-related cardiomyopathy. Proc. Natl Acad. Sci. USA 104, 5995-6000 (2007).
115. Konhilas, J. P. et al. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ. Res. 98, 540-548 (2006).
116. Care, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nature Med. 13, 613-618 (2007).
117. Fernandes, T. et al. Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors: role of microRNAs-16,-21, and-126. Hypertension 59, 513-520 (2012).
118. Porrello, E. R. et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ. Res. 109, 670-679 (2011).
119. van Rooij, E. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579 (2007).
120. Callis, T. E. et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119, 2772-2786 (2009).
121. Nishi, H. et al. MicroRNA-27a regulates β cardiac myosin heavy chain gene expression by targeting thyroid hormone receptor β1 in neonatal rat ventricular myocytes. Mol. Cell. Biol. 31, 744-755 (2011).